Abstract:Question Is metformin associated with improved outcomes among women with polycystic ovarian syndrome undergoing in vitro fertilization? Findings This meta-analysis of 12 randomized clinical trials, which collectively included 1123 women, found that metformin treatment was associated with a decreased risk of ovarian hyperstimulation syndrome among women with polycystic ovarian syndrome undergoing in vitro fertilization but had no association with clinical pregnancy or live birth rates in the total population studied. However, among women with a body mass index of 26 or greater, metformin treatment was associated with an improved clinical pregnancy rate. Meaning The findings of this study suggest that metformin treatment should be carefully considered for women with polycystic ovarian syndrome undergoing in vitro fertilization and may be more preferred among women with a body mass index of 26 or greater. This systematic review and meta-analysis assesses whether metformin is associated with improved outcomes of in vitro fertilization or intracytoplasmic sperm injection and embryo transfer among women with polycystic ovarian syndrome. Importance Metformin is widely used among women with polycystic ovary syndrome (PCOS). However, its associations with outcomes of in vitro fertilization or intracytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET) in women with PCOS remain controversial. Objective To assess whether metformin is associated with improved outcomes of IVF/ICSI-ET in women with PCOS. Data Sources PubMed, Embase, and Cochrane were searched from database inception to January 31, 2020. Study Selection Only randomized clinical trials (RCTs) were included. Eligible studies enrolled women with PCOS undergoing infertility treatment with IVF/ICSI-ET and reported at least 1 outcome of IVF/ICSI-ET. Data Extraction and Synthesis This study followed the Preferred Reporting Items for Systematic Reviews and Meta analyses guidelines. Two authors independently extracted the data. Study quality was evaluated using the GRADE system. Treatment effect was quantified using odds ratios (ORs) with 95% CIs using random-effect models with the Mantel-Haenszel method. Main Outcomes and Measures Ovarian hyperstimulation syndrome (OHSS), clinical pregnancy rate, and live birth rate. Results A total of 12 RCTs, which collectively included 1123 women with PCOS undergoing infertility treatment with IVF/ICSI-ET, were identified. The risk of OHSS in women randomized to metformin was lower than in women not randomized to metformin (OR, 0.43; 95% CI, 0.24-0.78), although this difference was not significant for women with PCOS with a body mass index of less than 26 (OR, 0.67; 95% CI, 0.30-1.51). There was no significant difference in clinical pregnancy rate (OR, 1.24; 95% CI, 0.82-1.86) or live birth rate (OR, 1.23; 95% CI, 0.74-2.04) in the total population studied. However, in a post hoc analysis among women with a body mass index of 26 or greater, metformin treatment was associated with increased clinical pregnancy rates (OR, 1.71; 95% CI, 1.12-2.60). Conclusions and Relevance In this study, metformin treatment was associated with a decreased risk of OHSS but had no association with the overall clinical pregnancy rate or live birth rate among women with PCOS undergoing IVF/ICSI-ET. Metformin treatment should be carefully considered for women with PCOS undergoing IVF/ICSI-ET and may be more preferred for women with a body mass index greater than 26.

Clinical Significance of Transvaginal Ultrasound Valuating Metformin Therapeutic Effect in Polycystic Ovary Syndrome Patients Accompanied by Insulin Resistance

Clinical effect of acupuncture combined with Chinese medicine in treatment of polycystic ovary syndrome and its influence on serum IL-6

Therapeutic Effect of Metformin on Patients with Polycystic Ovary Syndrome with Normal Insulin Sensitivity: A Retrospective Study

The Challenges of Stroke Prediction Scores.

RELATIONSHIP AMONG OVARIAN CHANGES ASSESSED BY TRANSVAGINAL ULTRASONOGRAPHY AND CLINICAL AND ENDOCRINIC FINDINGS OF THE POLYCYSTIC OVARY PATIENTS

Impact of Metformin on Blood Levels of Thyroid Function Tests, and Some Biochemical Parameters Levels in Polycystic Ovarian Women

Clinical effect of estrogen combined with metformin in the treatment of adolescent polycystic ovary syndrome

Efficacy of Metformin for Polycystic Ovary Syndrome:Evidence-based Evaluation

Effect of Metformin on Reproductive Endocrine and Glucose and Lipid Metabolism of Polycystic Ovary Syndrome Patients with or Without Central Obesity

Effect of metformin on insulin levels, blood sugar, and body mass index in polycystic ovarian syndrome cases

Clinical Observation of “kuntai Formula”for the Treatment of Polycystic Ovary Syndrome

Update on the Therapeutic Effects of Metformin in the Treatment of Polycystic Ovary Syndrome

Association of Serum Thyroid Hormone Levels with Androgen and Metabolic Parameters in Chinese Women with Polycystic Ovary Syndrome: A Retrospective Cross-Sectional Study

Evaluation of preliminary efficacy of comprehensive treatment for polycystic ovary syndrome

Delayed haemolytic transfusion reaction with renal failure.

Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization A Systematic Review and Meta-analysis

Effect of metformin combined therapy in patients with polycystic ovary syndrome

1516-P: Free Fatty Acid and Amino Acid Predictors of Response to Metformin in Polycystic Ovary Syndrome

Insulin Resistance, Polycystic Ovary Syndrome and Metformin

Impact of Gut Microbiota and SCFAs in the Pathogenesis of PCOS and the Effect of Metformin Therapy

The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethinyloestradiol on PCOS patients